Gilead Sciences Inc. closed $6.85 short of its 52-week high ($98.90), which the company achieved on November 11th.

Brubaker opened the second quarter with a basket, but Cameron Vickers scored four straight for the Indians to make it a 20-18 ...

HUNTERSVILLE, N.C., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation's leading builder of luxury ...

Padlock Therapeutics investors accused Bristol Myers of avoiding making milestone payments promised under a 2016 deal.

New York, United States - September 05, 2024 Demonstrators protest against Gilead Pharmaceuticals in midtown Manhattan.

Gilead Sciences, Inc. GILD announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European ...

• Northmor at East Knox, boys’ basketball, 4:30 p.m. • Danville at Cardington, boys’ basketball, 6 p.m. • Centerburg at Mount Gilead, boys’ basketball, 6 p.m. • Mount Gilead at New Albany, boys’ ...

US private investment firm AE Industrial Partners is acquiring Israeli cyberattack company Paragon Solutions, sources close ...

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $91.86 which represents a decrease of $-0.52 or -0.56% from the prior close of $92.38. The stock opened at $91.66 and touched a low ...

Gilead (GILD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Global Biologics Market Outlook to 2031The global biologics market was valued at US$ 515.6 billion in 2022 and is projected ...

New research revealed tumor mutational burden was linked to improved event-free survival with pembrolizumab in early TNBC, ...